DEO vs STZ vs BEAM vs SAM vs MGPI

For growth investors, Beam Therapeutics Inc.

(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -23. 8% for MGP Ingredients, Inc. (MGPI). Diageo plc (DEO) offers the better valuation at 19. 7x trailing P/E (17. 8x forward), making it the more compelling value choice. Analysts rate Constellation Brands, Inc. (STZ) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Diageo plc (DEO) is the cheapest at 19.

7x versus The Boston Beer Company, Inc. at 20. 5x. On forward P/E, MGP Ingredients, Inc. is actually cheaper at 12. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Constellation Brands, Inc.

(STZ) delivered a total return of -30. 1%, compared to -81. 8% for The Boston Beer Company, Inc. (SAM). Over 10 years, the gap is even starker: BEAM returned +67. 8% versus MGPI's -17. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Constellation Brands, Inc.

(STZ) is the lower-risk stock at 0. 26β versus Beam Therapeutics Inc. 's 2. 14β — meaning BEAM is approximately 719% more volatile than STZ relative to the S&P 500. On balance sheet safety, The Boston Beer Company, Inc. (SAM) carries a lower debt/equity ratio of 4% versus 185% for Diageo plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Beam Therapeutics Inc.

(BEAM) is pulling ahead at 120. 0% versus -23. 8% for MGP Ingredients, Inc. (MGPI). On earnings-per-share growth, the picture is similar: The Boston Beer Company, Inc. grew EPS 95. 5% year-over-year, compared to -419. 9% for MGP Ingredients, Inc.. Over a 3-year CAGR, BEAM leads at 31. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Diageo plc (DEO) is the more profitable company, earning 11.

6% net margin versus -57. 2% for Beam Therapeutics Inc. — meaning it keeps 11. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: STZ leads at 35. 5% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — BEAM leads at 84. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, MGP Ingredients, Inc.

(MGPI) trades at 12. 1x forward P/E versus 20. 6x for The Boston Beer Company, Inc. — 8. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MGPI: 51. 9% to $29. 00.

In this comparison, DEO (4.

9% yield), STZ (2. 7% yield), MGPI (2. 5% yield) pay a dividend. BEAM, SAM do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Constellation Brands, Inc.

(STZ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 26), 2. 7% yield). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (STZ: +12. 6%, BEAM: +67. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (DEO (Consumer Defensive) and STZ (Consumer Defensive) and BEAM (Healthcare) and SAM (Consumer Defensive) and MGPI (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: DEO is a mid-cap income-oriented stock; STZ is a mid-cap quality compounder stock; BEAM is a small-cap high-growth stock; SAM is a small-cap quality compounder stock; MGPI is a small-cap quality compounder stock. DEO, STZ, MGPI pay a dividend while BEAM, SAM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.